Antibe Therapeutics Inc
TSX:ATE

Watchlist Manager
Antibe Therapeutics Inc Logo
Antibe Therapeutics Inc
TSX:ATE
Watchlist
Price: 0.295 CAD Market Closed
Market Cap: CA$4.7m

Net Margin

0%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
CA$0
/
CA$0

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
CA$0
/
CA$0

Peer Comparison

Country Company Market Cap Net
Margin
CA
Antibe Therapeutics Inc
TSX:ATE
4.7m CAD
Loading...
US
Eli Lilly and Co
NYSE:LLY
954.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
546.2B USD
Loading...
CH
Roche Holding AG
SIX:ROG
269.4B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
208.2B GBP
Loading...
CH
Novartis AG
SIX:NOVN
218.2B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
265.4B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
147.6B USD
Loading...
FR
Sanofi SA
PAR:SAN
93.9B EUR
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Antibe Therapeutics Inc
Glance View

Market Cap
4.7m CAD
Industry
Pharmaceuticals

Antibe Therapeutics, Inc. is a biotechnology company, which engages in the development of medicines for pain and inflammation. The company is headquartered in Toronto, Ontario and currently employs 37 full-time employees. The company went IPO on 2013-06-18. The firm is focused on pain, inflammation, and regenerative medicine. The Company’s products pipeline includes Otenaproxesul, ATB-352, and ATB-340. Otenaproxesul is a novel anti-inflammatory drug that releases hydrogen sulfide and combines hydrogen sulfide with naproxen, non-steroidal, anti-inflammatory drug. ATB-352 is a hydrogen sulfide-releasing derivative of ketoprofen. ATB-340 is a gastrointestinal-safe version of low-dose aspirin for cardiovascular and cancer protection. The Company, through its wholly owned subsidiary, Citagenix Inc. (Citagenix) is a seller of tissue regenerative products servicing the orthopaedic and dental marketplaces. Citagenix’s portfolio consists of branded biologics and medical devices that promote bone regeneration.

ATE Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Back to Top